International Stem Cell Corporation (OTCBB:ISCO) today announced that
its wholly owned subsidiary, Lifeline Skin Care, has launched a new
marketing program. New promotional efforts include (1) rebranding the
line to feature Lifeline's unique selling proposition; (2) creating
greater consumer awareness through public relations as well as online
marketing; and (3) re-marketing to existing users to strengthen brand
loyalty. Research has established that the brand's proprietary stem cell
technology is a critical point of difference in the skincare market, and
it's also the reason to believe in the brand. New marketing materials
feature the headline, "Someday, stem cells will change the world. Today,
stem cells will change your skin." This messaging is now being
communicated through online and traditional marketing and sales
promotion materials.
The current marketing program follows six months in which little or no
marketing was done by the company because initial sales that were booked
in January from a December 2010 launch had far exceeded expectations
and, as a result, also exceeded supplies of the unique stem cell extract
that is the key ingredient in the Lifeline Skin Care products. The
company has now built a substantial reserve inventory of the essential
stem cell extract and has also designed new marketing programs to both
minimize sudden surges in demand and permit controlled testing of new
products and sales initiatives. The company has also re-engineered its
quality control, logistics and customer service to deliver higher
quality products and services to the consumer.
"Sales for the first two weeks of the new program were approximately
1,000 units, which is in line with our expectations and does not include
any sales from pending initiatives to spas and medical clinics or
international sales," said Donna Queen, Vice President of Marketing and
Business Development.
"In keeping with the reporting practices of its parent company,
International Stem Cell Corporation, revenue data will not be released
except on a quarterly basis, but Lifeline Skin Care will continue to
advise its customers and ISCO investors of new sales initiatives as a
way of increasing customer awareness and referral business," said Dr.
Ruslan Semechkin, President and CEO of Lifeline Skin Care. As previously
announced, International Stem Cell Corporation defers all revenues
associated with Lifeline Skin Care products until the 30 day right of
return guarantee expires.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and cosmetic
products. ISCO's core technology, parthenogenesis, results in the
creation of pluripotent human stem cells from unfertilized oocytes
(eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells for hundreds of millions of individuals of differing
genders, ages and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true stem
cell bank, UniStemCell™. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary Lifeline Cell Technology, and cell-based skin care products
through its subsidiary Lifeline Skin Care. More information is available
at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, and other
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, including the expected results of
enhancements in Lifeline Skin Care marketing efforts, constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, competition, need and ability to
obtain future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth
C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lifeline
Skin Care, Inc
Donna Queen, Vice President
760-940-6383
dqueen@lifelineskincare.com
or
Lippert/Heilshorn
& Associates
Don Markley, 310-691-7100
dmarkley@lhai.com